NCT03085719View on ClinicalTrials.gov

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

November 1, 2022

Study Completion Date

October 31, 2027

Conditions
Head and Neck Cancer
Interventions
DRUG

Pembrolizumab

Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells

RADIATION

Radiation

Radiation is used to shrink the cancer

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER